Zacks Research Boosts Earnings Estimates for Zimmer Biomet

Key Points

• Zacks Research has raised its FY2026 earnings per share (EPS) estimate for Zimmer Biomet to $8.12, slightly up from the previous estimate of $8.11.
• The company reported $2.07 EPS for Q2, exceeding estimates by $0.09, and achieved a revenue of $2.08 billion, a 7.0% increase year-over-year.
• Zimmer Biomet recently announced a quarterly dividend of $0.24 per share, resulting in an annualized yield of 1.0%, with the dividend payable on October 31st.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Zimmer Biomet in a research report issued to clients and investors on Tuesday, September 23rd. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $8.12 per share for the year, up from their prior estimate of $8.11. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's Q4 2026 earnings at $2.08 EPS, Q1 2027 earnings at $2.12 EPS and FY2027 earnings at $8.72 EPS.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the company posted $2.01 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS.

A number of other analysts have also recently commented on the stock. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a "buy" rating and a $130.00 target price for the company. Rothschild Redb upgraded Zimmer Biomet to a "strong-buy" rating in a report on Thursday, September 18th. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Royal Bank Of Canada raised their target price on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Raymond James Financial boosted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $113.16.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $100.29 on Wednesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The stock has a market capitalization of $19.87 billion, a PE ratio of 24.40, a P/E/G ratio of 2.34 and a beta of 0.68. Zimmer Biomet has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The company has a fifty day moving average of $100.35 and a two-hundred day moving average of $99.32.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Ameriprise Financial Inc. grew its holdings in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the period. Dodge & Cox boosted its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider's stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the last quarter. Norges Bank purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $225,867,000. JPMorgan Chase & Co. increased its holdings in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after buying an additional 1,488,918 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $155,891,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.